From a recent research, the prevalence of prior cancer among people who have been newly diagnosed with cancer from 2009 to 2013 through Surveillance of the National Cancer Institute is presented. There was a total of 765,843 incidences of cancer diagnosis among 740,990 people from 2009 to 2013. Out of the number, 18.4% represents a second order of higher primary cancer. The prevalence of prior cancer was found to differ with age; 11.0% among those aged between 20 and 64 and 25.2% among those who are above 65 years. The prevalence was also found to differ with the incident type of canal, rectum, monocytic leukemia and other female genital organs.
During the research, it was not possible to determine the order of multiple cancers diagnosed in the same year because only the year of diagnosis is available in the SEER data. Prior cases of cancer diagnosed outside registry geographic areas are represented only in sequence numbers with no corresponding information on previous cancer characteristics. These limitations, however, only account for 5% of the total cases of cancer in the study thus has a small impact on the conclusion. The conclusion, therefore, is that understanding the nature and impact of a prior cancer is critical for the improvement of trial accrual and the generalization of results from the observational studies and trials.
Eric Lefkofsky went to the University of Michigan. He is the chief executive officer of Tempus and the co-founder of Echo Global Logistics. Eric Lefkofsky has participated in a number of philanthropic activities. In 2006, he formed the Leftkofsky Foundation which is a charitable trust with the goal of supporting educational organizations and charitable activities all over the world.
Eric Lefkofsky and his wife Elizabeth joined the Giving Pledge in 2013.
Eric Lefkofsky is on the board of directors for several organizations which include; The Museum of Science and Industry, Children’s Memorial Hospital, and The Art Institute of Chicago. Eric Lefkofsky has donated several millions of dollars towards cancer research. He remains one of the most influential tech figures in Chicago and is currently working on a better approach to curing cancer.